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Objectives Our aim was to investigate the effects of reconstituted high-density lipoprotein (rHDL) infusions on plasma high-
density lipoprotein (HDL) anti-inflammatory properties and ex vivo cholesterol efflux in patients with type 2 diabetes.
Background The anti-inflammatory effects of HDL contribute to protection from cardiovascular events. Individuals with type 2
diabetes are at elevated risk for cardiovascular disease, and typically have low HDL with reduced anti-inflammatory
properties.
Methods Thirteen fasting male patients (mean age 52 years) with type 2 diabetes mellitus received both rHDL (80 mg/kg
of apolipoprotein A-I) and a saline placebo on separate occasions in a randomized cross-over design study.
Changes in the ability of isolated HDL to influence the expression of intercellular adhesion molecule-1 and vas-
cular cell adhesion molecule-1 in human coronary artery endothelial cells was the main outcome measure.
Other outcome measures included expression of the key integrin, CD11b on patient monocytes, adhesiveness of
patient neutrophils to fibrinogen, and the ability of plasma to promote cholesterol efflux to THP-1 macrophages.
Results Four and 72 h post-rHDL infusion, the anti-inflammatory properties of isolated HDL increased in parallel to their
concentration in plasma (by up to 25%, p  0.01). Participants’ peripheral blood monocyte CD11b expression
and neutrophil adhesion to a fibrinogen matrix was also reduced 72 h post-rHDL, compared with that seen in
placebo (p  0.02). rHDL increased the capacity of plasma to receive cholesterol from THP-1 macrophages by
1 h up to 72 h post-infusion (by 40% to 60%, p  0.05).
Conclusions rHDL infusions have significant, potentially atheroprotective effects in individuals with diabetes, including sup-
pression of inflammation and enhancement of cholesterol efflux. (J Am Coll Cardiol 2009;53:962–71) © 2009
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.008a
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carge epidemiologic studies have established that low serum
evels of high-density lipoprotein (HDL) are a significant
nd independent predictor of adverse cardiovascular events
1–6). These cardioprotective effects of HDL are thought to
e due, in part, to their ability to mediate reverse cholesterol
ransport (7) and to inhibit athero-inflammation (8,9),
hereby potentially reducing atherosclerotic plaque burden
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hat infusions of reconstituted high-density lipoprotein
rHDL) and recombinant HDL in humans with known
oronary artery disease significantly (albeit modestly) re-
uced plaque volume and had favorable effects on plaque
orphology as assessed by intravascular ultrasound (10,11).
oreover, infusions of rHDL have beneficial effects on
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March 17, 2009:962–71 Reconstituted HDL Is Anti-Inflammatoryndothelial function in patients with type 2 diabetes (12)
nd hypercholesterolemia (13). The effects of rHDL on
ascular inflammation, however, have not previously been
tudied in humans.
We hypothesized that infusions of rHDL in humans
ould enhance the anti-inflammatory properties of plasma
DL. To test this hypothesis, we examined the effects of
HDL infusions on key aspects of HDL structure and
nti-inflammatory properties. This study was conducted in
he context of type 2 diabetes mellitus, where HDL levels
re typically low and HDL particles may be subject to
odification by advanced glycation end products and, thus,
ay be less effective in their ability to mediate cholesterol
fflux and suppress inflammation (14–17). We also assessed
he effects of rHDL infusion on other important aspects of
therogenesis ex vivo, including patient leukocyte integrin
xpression and cholesterol-effluxing capacity of plasma. Our
esults indicate that rHDL infusions significantly increase
he amount of HDL in plasma, leading to a parallel increase
n the anti-inflammatory properties of the isolated plasma
DL lasting up to 72 h. We also report important benefi-
ial effects on leukocyte function as well as significant
nhancement of plasma cholesterol-effluxing capacity.
ethods
nclusion and exclusion criteria. Studies were approved
y the Alfred Hospital Ethics Committee, performed in
ccordance with the Declaration of Helsinki, and informed
ritten consent was obtained from all participants. Potential
articipants were screened for type 2 diabetes mellitus using
tandard criteria (fasting plasma glucose 7.1 mmol/l or a
-h blood glucose level of 11.1 mmol/l after a 70-g oral
lucose load [oral glucose tolerance test]). Those with a
revious history of major illness including coronary heart
isease were excluded. Patients on peroxisome proliferator-
ctivated receptor agonists (fibrates or thiazolidinediones),
etformin, lipid-modifying therapy, or anticoagulants were
lso excluded. Patient characteristics, medications, and
afety profiles are presented in Table 1.
HDL constituents and preparation. rHDL was supplied
y CSL Behring AG (Bern, Switzerland) (18). The rHDL
as prepared fresh for each study by the Alfred Hospital
harmacy. rHDL consisted of apolipoprotein (apo) A-I
solated from human plasma and phosphatidyl choline from
oy bean. ApoA-I and phosphatidyl choline were combined
n the presence of sodium cholate in a molar ratio of 1:150
nd form disc-shaped, noncovalently associated particles
esembling nascent HDL. The final product was lyophi-
ized. Before infusion, the lyophilized product was recon-
tituted with sterile water for injection. The final concen-
ration was 20 mg of apoA-I per milliliter of solution. This
reparation has been demonstrated to produce biological
esponses analogous to native HDL in previous studies
13,19,20). cHDL infusion protocol. Thir-
een patients with type 2 diabetes
ellitus were included in a pla-
ebo (saline)-controlled, double-
lind, cross-over study of the
cute effects of rHDL. The 2
nfusions were administered in
andom order and separated by at
east 4 weeks. For each visit,
articipants fasted overnight and
rrived at the laboratory at 8 AM.
wo catheters were inserted into
ntecubital veins, 1 in each arm.
he left arm catheter was uti-
ized to administer the drug infusion (rHDL 80 mg/kg; or
lacebo [saline] over 4 h) by calibrated infusion pump while
he right arm catheter was dedicated for blood sampling.
ach participant was required to return 72 h post-infusion
or further blood sampling. There was no interaction be-
ween order of intervention (rHDL and placebo) and time
r treatment for any of the variables tested.
lasma lipid parameters and inflammatory markers. Blood
rom participants was collected into the appropriate antico-
gulant, and plasma was immediately separated by centrif-
gation and snap frozen. HDL cholesterol was measured by
Abbreviations
and Acronyms
apo  apolipoprotein
HDL  high-density
lipoprotein
ICAM  intercellular
adhesion molecule
rHDL  reconstituted high-
density lipoprotein
s  soluble
VCAM  vascular cell
adhesion molecule
articipant Characteristics
Table 1 Participant Characteristics
Characteristic Mean  SEM
Age (yrs) 51.8 2.0
Height (cm) 176.9 2.0
Weight (kg) 107.8 7.8
BMI (kg/m2) 34.3 2.3
Fasting glucose (mmol/l) 10.5 1.0
HbA1c (%) 7.8 0.6
2-h OGTT (mmol/l) 13.9 1.0
HDL-C (mmol/l) 1.02 0.04
Total cholesterol (mmol/l) 4.98 0.26
LDL-C (mmol/l) 3.06 0.27
Triglycerides (mmol/l) 2.09 0.39
Medications
Medication No. Medicated (n  13)
Glibenclamide 1
Gliclazide 4
Glimepiride 1
Safety Profile
Measure Baseline 4 h 72 h
Headache — 2/13 0/13
Fever — 0/13 0/13
Nausea — 1/13 0/13
Alanine transaminase (U/l) 39.6 5.2 32.1 3.4 47.0 6.2
Gamma-glutamyl
transpeptidase (U/l)
47.0 9.4 38.6 6.5 47.6 8.0
Alkaline phosphatase (U/l) 82.6 5.8 63.3 4.4 78.0 5.3
ll continuous variables are expressed as mean  standard error of the mean (SEM) (n  13).
BMI  body mass index; HbA1c  glycosylated hemog
holesterol; LDL-C  low-density lipoprotein cholesterol; O
lobin; HDL-C  high-density lipoprotein
GTT  oral glucose tolerance test.
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Reconstituted HDL Is Anti-Inflammatory March 17, 2009:962–71olorimetric assay per manufacturer instructions (WAKO
ure Chemical Industries, Osaka, Japan). ApoA-I protein
as analyzed in plasma by enzyme-linked immunosorbent
ssay per manufacturer instructions (Alerchek, Portland,
regon). Plasma soluble intercellular adhesion molecule
sICAM)-1 and soluble vascular cell adhesion molecule
sVCAM)-1 were measured by enzyme-linked immunosor-
ent assay per the manufacturer instructions (Bender Med-
ystems, Vienna, Austria). Plasma C-reactive protein was
easured by high-sensitivity turbidimetric assay (Roche,
asel, Switzerland).
solation and characterization of HDL. The total HDL
raction (1.063  density 1.21 g/ml) was isolated from
lasma at baseline and at 4 and 72 h post-infusion by
equential ultracentrifugation and dialyzed against endotoxin-
ree phosphate-buffered saline (21). All compositional anal-
ses were performed on a Roche Diagnostics/Hitachi 902
utoanalyzer (Roche Diagnostics, Mannheim, Germany).
rotein, triglyceride, and phospholipid concentrations were
etermined using established techniques (22–24). Total
holesterol concentrations were quantitated enzymatically
sing a Roche Diagnostics kit (Basel, Switzerland). Un-
sterified (free) cholesterol concentrations were assayed
nzymatically (25). Cholesteryl ester concentrations were
etermined by subtracting the concentration of unesterified
holesterol from the total cholesterol concentration (in
mol/l). The mass of unesterified cholesterol was calculated
rom the molar concentration using the molecular weight of
holesterol. The cholesteryl ester mass (including both the
holesterol and fatty acid components) was calculated from
he molar concentration using the molecular weight of a
ypical HDL cholesteryl ester (approximately 650). Phos-
holipid and triglyceride mass was similarly calculated using
nown molecular weights of phospholipid and triglyceride.
poA-I and apoA-II composition was determined immu-
oturbidometrically using sheep antihuman apoA-I (26)
nd apoA-II (27) polyclonal antibodies, respectively. HDL
ize was determined by nondenaturing polyacrylamide gel
lectrophoresis (28) and quantified using ImageQuant TL
GE Healthcare, Piscataway, New Jersey) software. HDL
urface charge was determined by agarose gel electrophore-
is (29).
x vivo endothelial cell adhesion molecule expression. HDL
as isolated from equivalent plasma volumes at 0, 4, and
2 h post-infusion. Because the plasma apoA-II concentra-
ion did not change with infusion of either saline or rHDL
Fig. 1, bottom), HDL was incubated with cultured human
oronary artery endothelial cells (Lonza Bioscience, Basel,
witzerland) at increasing HDL apoA-II concentrations (1
o 8 mol/l), in growth media, for 16 h at 37°C. Cells were
hen stimulated with tumor necrosis factor-alpha (0.1 ng/
l), and 5 h later the cellular expression of the adhesion
olecules VCAM- and ICAM-1 were determined by flow
ytometry (30) (Beckman Coulter FC 500, Fullerton, Cal-
fornia). Cell viability was determined by a lactate dehydro- Oenase release assay and found to be 90% in all
xperiments.
lasma monocyte activation. CD11b expression on pe-
ipheral blood monocytes from patients was measured in
hole blood as a marker of monocyte activation before and
2 h after both infusions. Peripheral blood anticoagulated
ith citrate was incubated with an antihuman CD11b
ntibody (Serotec, Clone ICRF44, Oxford, United King-
om) for 15 min at 37°C. Cells were fixed and lysed with
Figure 1 Plasma HDL-C, ApoA-I, and ApoA-II
Plasma concentration of high-density lipoprotein cholesterol (HDL-C) (top) and
apolipoprotein (apo) A-I (middle) and apoA-II (bottom) during the 4-h infusions
and at 72 h post-infusion (n  13). Closed circles  reconstituted high-density
lipoprotein (rHDL); open circles  saline placebo. Data are mean  standard
error of the mean. *Denotes a significant treatment effect versus placebo
(baseline values assessed before treatment were not included in analysis of
variances), p  0.05.ptiLyse B (Immunotech, Prague, Czech Republic) for 10
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March 17, 2009:962–71 Reconstituted HDL Is Anti-Inflammatoryin. The lysis process was completed with the addition of
istilled water. Analyses were controlled using the isotype-
atched negative control antibody (FITC-antimouse IgG,
erotec, Clone W3/25). CD11b expression on monocytes
as measured by flow cytometry (FACS Calibur, Becton
ickinson, Franklin Lakes, New Jersey); the monocyte
opulation was identified by size and granularity profiles.
nalysis was conducted using Cell Quest Pro software
version 3.3, BD BioSciences, Franklin Lakes, New Jersey).
lasma neutrophil adhesion to immobilized fibrinogen. Neu-
rophils are more abundant in coronary disease patients
31,32), and their adhesion at the site of atheroma contrib-
tes to disease progression (33) and acute events (34).
dhesion of neutrophils from patients before and 72 h after
oth infusions to immobilized fibrinogen was assessed.
ollowing the method of Woollard et al. (35), glass cover
lips (Ø 12 mm) in 24-well plates were coated with
brinogen (100 g/ml) at 4°C overnight. Neutrophils (1 
06/ml) were added for 15 min at 37°C in 300 l of plasma.
over slips were then removed and adhered cells fixed in 4%
ormaldehyde for 30 min. Cover slips were washed by
areful submersion in water, dried, and mounted on glass
lides using mounting medium (Dako, Glostrup, Den-
ark). Neutrophil adhesion was quantified by phase mi-
roscopy (40 objective), counting 5 random fields from
ach slide. Treatments were carried out in triplicate.
x vivo cholesterol efflux. The capacity of plasma samples
o support cholesterol efflux was analyzed ex vivo using the
uman monocyte cell line THP-1. Cells were activated with
n LXR agonist (TO901317, 1 mol/l) to enhance the
xpression of ABC transporters, but were not loaded with
xcessive cholesterol. THP-1 human monocyte cells were
eeded into 12 well plates at density of 8  107 cells per
ell. Cells were differentiated to macrophages with phorbol
2-myristate-13-acetate (final concentration 100 ng/ml),
nd cellular cholesterol was labeled by incubation in serum-
ontaining medium with [1,2(n)-3H]-cholesterol (GE
ealthcare, Buckinghamshire, United Kingdom) (final ra-
ioactivity 0.5 MBq/ml) for 48 h in a CO2 incubator. Cells
ere then washed and incubated for 18 h at 37°C in
erum-free medium containing the LXR agonist, TO-
01317 (final concentration 1 mol/l). Cells were washed
gain and incubated for another 2 h at 37°C in serum-free
edium containing patient plasma at the final concentra-
ion of 2%. Medium was collected and centrifuged, then
liquots of supernatant were counted in liquid scintillation
n a beta-counter. Cells were also harvested, and radioac-
ivity counted as for supernatant. Cholesterol efflux was
xpressed as the proportion of [3H]-cholesterol transferred
rom cells to medium. Background values (i.e., the efflux in
he absence of plasma) were subtracted.
tatistics. Time course data were compared using repeated
easures analysis of variance to both baseline and with
lacebo as indicated in the text and figure legends. Com-
arisons between treatments included treatment order as a
etween-subject variable. Individual mean comparisons iere made using a least significant difference post hoc test.
earson correlation coefficients were calculated to determine
he relationship between concentration of HDL constitu-
nts and cell adhesion molecule expression. All data were
nalyzed using SPSS for Windows (version 15, SPSS Inc.,
hicago, Illinois) and Sigmastat for Windows (version 3.5,
ystat, San Jose, California) and are expressed as mean 
tandard error of the mean. A value of p 0.05 was deemed
ignificant.
esults
lasma HDL and apoA-I levels. HDL was significantly
levated from 3 h (p  0.009) into the rHDL infusion
relative to placebo), continued to rise throughout the 4-h
nfusion to 51  5% above placebo (p  0.001), and
emained at 55  8% (p  0.001) above placebo at 72 h
ost-infusion (ptreatment  0.001) (Fig. 1, top). ApoA-I was
levated from 1 h (p  0.005) into the rHDL infusion
relative to placebo) and continued to rise to 126  12%
bove placebo at 4 h (p 0.001). By 72 h, apoA-I levels had
eclined but remained 61  7% (p  0.001) above placebo
ptreatment  0.001) (Fig. 1, middle). Plasma apoA-II
oncentrations did not significantly change with infusion of
ither saline or rHDL (Fig. 1, bottom).
DL size. The size of the plasma HDL particles, isolated
rom participants infused with rHDL or saline, was assessed
y subjecting aliquots of the isolated HDL (10 l) to
ondenaturing gradient gel electrophoresis. At baseline, 1
opulation of particles was observed (8.2 nm in diameter).
t 4 h post-infusion, 2 new populations of HDL particles
ere formed (8.0 and 8.9 nm in diameter), with disappear-
nce of the original population. By 72 h, only a single HDL
opulation of particles 8.3 nm in diameter was apparent.
he sizes of the new HDL particles formed post-rHDL
nfusion were clearly distinct from the infused rHDL (11.8
o 14.8 nm) (Fig. 2). Saline infusion did not affect the size
f the isolated HDL (not shown). Infusion with either
aline or rHDL had no effect on HDL surface charge (not
hown), with isolated HDL found in the alpha-migrating
osition only, with no pre-beta particles visualized.
DL composition. Saline infusion did not significantly
lter HDL composition (not shown). After rHDL infusion,
he phospholipid content of isolated HDL was significantly
ncreased at 4 and 72 h relative to other HDL constituents
Table 2). The apoA-I, apoA-II, triglyceride, and free and
sterified cholesterol content of isolated HDL were all
ignificantly decreased at 4 h post-rHDL infusion. At 72 h,
he proportion of apoA-I and apoA-II remained decreased
elative to what was observed at baseline.
ndothelial cell adhesion molecule expression. To deter-
ine if infusions of rHDL affected the anti-inflammatory
roperties of the plasma HDL fraction, the HDL was
solated from equivalent volumes of plasma by sequential
ltracentrifugation at 0, 4, and 72 h post-infusion. Saline
nfusion had no effect on the anti-inflammatory properties
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Reconstituted HDL Is Anti-Inflammatory March 17, 2009:962–71f isolated HDL. At a final apoA-II concentration of 4
mol/l, VCAM-1 expression was inhibited by 9  2%, 11 
%, and 7  2% at 0, 4, and 72 h post-saline infusion,
espectively. Similarly, ICAM-1 expression was inhibited by
 2%, 7  4%, and 9  5%, at 0, 4, and 72 h post-saline
nfusion, respectively.
Post-rHDL infusion, HDL isolated at 4 h and 72 h
nhibited VCAM- and ICAM-1 expression to a signifi-
antly greater extent, compared with HDL isolated at
aseline. These differences were apparent at an HDL
poA-II concentration of 4 mol/l (Figs. 3A and 3D). A
imilar pattern was observed when these experiments were
onducted at HDL apoA-II concentrations of 1, 2, and 8
mol/l. VCAM- and ICAM-1 expression correlated sig-
ificantly with HDL apoA-I concentration (R  0.68 and
 0.51, respectively, p  0.01 for both) (Figs. 3B and
E), HDL phospholipid concentration (R  0.58 and R 
.46 respectively, p  0.01) (Figs. 3C and 3F), HDL
holesterol ester concentration (R  0.67 and R  0.4
espectively, p  0.01 for both), and HDL free cholesterol
oncentration (R  0.66 and R  0.51, respectively, p 
.01 for both), but not with HDL apoA-II concentration
R  0.13 and R  0.16, respectively). The magnitude of
Figure 2 Isolated HDL Size
Participants (n  13) were infused with rHDL (80 mg/kg) and plasma was col-
lected at baseline and at 4 and 72 h post-infusion. HDL was ultracentrifugally
isolated from plasma as described in the Methods section. Aliquots of HDL
(10 l) were subjected to nondenaturing polyacrylamide (3% to 40%) gradient
gel electrophoresis. The gels were subsequently Coomassie stained and HDL
size quantified using ImageQuant TL software. A gel from 1 representative sub-
ject is shown. The numbers on the left hand side of the gel represent sizes of
high molecular weight standards of known diameter. Abbreviations as in Figure 1.CAM- and ICAM-1 inhibition is, therefore, proportional to the amount of HDL that was included in the incubations,
s evidenced by significant correlations with all HDL
onstituents (apart from apoA-II) and CAM expression.
lasma sICAM- and sVCAM-1. Plasma sVCAM-1 lev-
ls were significantly reduced after the 4-h rHDL infusion,
ut had returned to baseline 72 h after the infusion (analysis
f variance time effect and treatment-time interaction both
 0.04) (Fig. 4, top). There was no significant effect of
HDL on circulating sICAM-1 levels (Fig. 4, bottom).
here was also no significant effect of rHDL on plasma
RP at either 4 or 72 h (placebo 2.74  0.54 mg/l vs.
HDL 2.98  0.87 mg/l) post-infusion.
eukocyte CD11b expression and neutrophil adhe-
ion. Monocyte CD11b expression was expressed as a per-
entage change from baseline levels 72 h after the placebo and
HDL infusions. While there was a trend for increased
xpression with placebo, CD11b expression was significantly
educed relative to placebo after rHDL (p  0.021) (Fig. 5,
op). This corresponded with a significant reduction in neu-
rophil adhesion to fibrinogen with rHDL (p 0.026) (Fig. 5,
ottom).
holesterol efflux. Relative to baseline, rHDL enhanced the
apacity of plasma to support cholesterol efflux by 35  7%
fter only 1 h (p  0.002) into the infusion and remained
levated at this level during the remaining infusion time and
2 h (p  0.018) after the infusion) (Fig. 6, top). This effect
as also observed when assessed relative to placebo 3 h into the
nfusion and 72 h post-infusion (Fig. 6, bottom). Cholesterol
fflux was significantly higher after the rHDL infusion by
pproximately 40% (p 0.021) and 60% (p 0.002) at 3 and
2 h, respectively (ptreatment 0.007). Interestingly, the capac-
ty of plasma to support cholesterol efflux did not increase
urther during the continued infusion despite a further rise in
lasma apoA-I and HDL-C levels (Fig. 1). Consequently
here was no statistically significant correlation between cho-
esterol efflux and plasma apoA-I or HDL cholesterol levels.
iscussion
n this study, we show for the first time that infusions of
HDL in patients with type 2 diabetes mellitus increase the
nti-inflammatory properties of the resulting plasma HDL
omposition of High-Densityipopr te ns A ter rH L Infusion
Table 2 Composition of High-DensityLipoproteins After rHDL Infusion
Baseline 4 h 72 h
ApoA-I 32.7 1.9 24.9 1.7* 27.6 3.3*
ApoA-II 15.4 3.6 4.0 0.5* 9.2 1.3*
PL 27.0 2.4 57.3 3.5* 36.5 2.3*
CE 19.1 2.5 10.1 1.3* 21.2 2.4
FC 1.7 0.4 1.3 0.1* 1.5 0.3
TG 4.0 0.5 2.6 0.8* 3.9 0.6
omposition (mass %) of high-density lipoproteins isolated from participants (n 13) at baseline and
and 72 h after infusion of reconstituted high-density lipoprotein (rHDL), expressed as mean 
tandard error of the mean (measures in triplicate). *p  0.05 by comparison with baseline values.
apo  apolipoprotein; CE  cholesterol ester; FC  free cholesterol; PL  phospholipid; TG 
riglyceride.
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March 17, 2009:962–71 Reconstituted HDL Is Anti-Inflammatoryraction, as demonstrated by its ability to inhibit the cellular
xpression of VCAM-1 and ICAM-1 on stimulated human
oronary endothelial cells. Furthermore, the magnitude of
nhibition was in proportion to the increase in the plasma
oncentration of HDL. Infusion of rHDL also resulted in
educed CD11b expression on circulating monocytes and
educed adhesion of patient neutrophils to fibrinogen and
Figure 3 Endothelial Cell Adhesion Molecule Expression
Participants (n  13) were infused with reconstituted HDL (80 mg/kg), and plasm
as described in the Methods section. Cultured human coronary artery endothelial
final apolipoprotein A-II concentration of 4 mol/l. The cells were then stimulated
vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICA
show VCAM-1 and ICAM-1 expression (mean  standard error of the mean) in the
tuted HDL infusion. The solid squares in C and D show VCAM- and ICAM-1 expres
the HDL preparations (R  0.68 and R  0.51, respectively, p  0.01 for both). T
phospholipid concentration (mean  standard error of the mean) of the HDL prepa
pared with baseline (0 h). PL  phospholipid; other abbreviations as in Figure 1.nhanced ex vivo cholesterol efflux (20) capacity of plasma. tThere are now robust data demonstrating the anti-
nflammatory properties of HDLs (36). In vitro studies have
hown that discoidal rHDL consisting of apoA-I com-
lexed with phosphatidylcholine inhibits the cellular expres-
ion of VCAM-1 and ICAM-1 on stimulated endothelial
ells (30,37,38). Similarly, HDL isolated from human
lasma inhibits cell adhesion molecule expression ex vivo,
collected at 0, 4, and 72 h post-infusion. The HDL was ultracentrifugally isolated
ere pre-incubated at 37°C for 16 h with the ultracentrifugally isolated HDL at a
mor necrosis factor-alpha (final concentration 0.1 ng/ml) for 5 h. Expression of
n the endothelial surface was determined by flow cytometry. Panels A and B
ce of HDL and in the presence of isolated HDL at 0, 4, and 72 h post-reconsti-
a function of the apoA-I concentration (mean  standard error of the mean) of
lid squares in E and F show VCAM- and ICAM-1 expression as a function of the
s (R  0.58 and R  0.46, respectively, p  0.01 for both). *p  0.01 com-a was
cells w
with tu
M)-1 o
absen
sion as
he so
rationhough this inhibition varies between individuals (36).
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Reconstituted HDL Is Anti-Inflammatory March 17, 2009:962–71urthermore, in rabbits, infusions of rHDL significantly
nhibit vascular inflammation induced by insertion of a
onocclusive silastic collar around the carotid artery (8). The
poA-I mimetic peptide D-4F has also been shown to have
nti-inflammatory properties in animal models (39–42),
nd rHDL has anti-inflammatory properties in the context
f human endotoxemia (43). Although previous studies
nfusing rHDL in humans have focused on atheroma
egression and plaque morphology, as assessed by intravas-
ular ultrasound (10), no study has specifically investigated
he potential vascular anti-inflammatory effects of rHDL
nfusion in humans.
The rHDL dose (80 mg/kg) was based on previous
tudies demonstrating beneficial effects on endothelial func-
ion (12,13,19) and plaque morphology (10). Tardif et al.
10) compared 40 mg/kg versus 80 mg/kg rHDL, and
lthough there was no difference in the overall frequency of
ajor adverse events between the treatment and placebo
roups, alanine aminotransferase levels exceeded 100-fold of
he upper limit of normal in some patients in the 80 mg/kg
roup. The patients in the current trial were early stage,
ell-controlled diabetic patients, and rHDL treatment at 80
g/kg was not associated with any significant liver function
Figure 4 Plasma sVCAM-1 and sICAM-1
Plasma concentration of soluble vascular cell adhesion molecule (sVCAM)
(top) and soluble intercellular adhesion molecule (sICAM) (bottom) during the
4 h infusions and at 72 h post-infusions (n  13). Solid circles  reconsti-
tuted high-density lipoprotein (rHDL); open circles  saline placebo. Data are
mean  standard error of the mean. *Denotes a significant treatment-time
interaction, p  0.05.bnormalities (Table 1, bottom). Since we show that anti-nflammatory effects parallel HDL concentration, we would
xpect a proportionally lesser, but clinically significant,
nti-inflammatory response at a dose of 40 mg/kg.
In the current study, experiments on cell adhesion mol-
cule expression were conducted with isolated HDL, as
pposed to whole plasma. We thus avoided the potentially
onfounding effects of other plasma components, which
nabled us to observe direct HDL-mediated changes on
hese cells. The anti-inflammatory properties of the plasma
DL were significantly increased at 4 h and even at 72 h
ost-rHDL infusion. These inhibitory effects were associ-
ted with increases in all HDL constituents apart from
poA-II, suggesting that the anti-inflammatory properties
f these particles in plasma post-infusion is related to the
otal amount of HDL in plasma, and not to an increased
oncentration in one particular constituent. Our results do
ot suggest that rHDL infusions lead to an increased
nti-inflammatory capacity of plasma HDL particles, inde-
endent of their plasma concentration.
Changes in isolated HDL size were also observed post-
HDL infusion, from a single population of particles pre-
nfusion, to a new larger population with an additional
lightly smaller population at 4 h, before returning to a
ingle population similar to baseline at 72 h. The presence
Figure 5 Leukocyte CD11b
Expression and Neutrophil Adhesion
(Top) Percentage change in monocyte CD11b expression pre- and 72 h post-
placebo (open bars) and reconstituted high-density lipoprotein (rHDL) (solid
bars) infusions (n  13). (Bottom) Change in neutrophil adhesion to fibrinogen
matrix pre- and 72 h post-placebo (open bars) and rHDL (solid bars) infusions.
Data are expressed as mean  standard error of the mean. *Denotes a signif-
icant difference between placebo and rHDL, p  0.05.
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March 17, 2009:962–71 Reconstituted HDL Is Anti-Inflammatoryf the larger population of particles at 4 h may reflect
ncorporation of infused apoA-I and phospholipids into the
ndogenous HDL as suggested by Nanjee et al. (20).
ndeed, our HDL compositional data, demonstrating a
ignificant increase in phospholipid content relative to other
onstituents, suggests that it may play a particular role in
ransiently increasing plasma HDL size post-rHDL infu-
ion. The remodeling of the larger particles by cholesterol
ster transfer protein, hepatic lipase (44,45), and/or phos-
holipid transfer protein (46) may account for the presence
f the smaller HDL particles at 4 h. The improvement in
DL anti-inflammatory capacity only occurred in propor-
ion to the amount of HDL in plasma, irrespective of
hether it was altered in size (4 h) or similar in size to
aseline (72 h). However, it has been postulated that the
nti-inflammatory capacity of HDL may be dependent
n its subclasses, where HDL3 has been shown to be
ore potent than HDL2 in inhibiting adhesion molecule
xpression on endothelial cells. There is some evidence
hat phospholipid content may account for these obser-
Figure 6 Cholesterol Efflux
(Top) Cholesterol efflux from THP-1 macrophages to 2% plasma taken at 1-h
intervals during the reconstituted high-density lipoprotein (rHDL) infusion and
72 h after infusion. *Denotes a significant difference from baseline (ptime 
0.05). (Bottom) Cholesterol efflux from THP-1 macrophages to 2% plasma
taken during both the placebo (open circles) and rHDL (solid circles) interven-
tions at baseline, 3 h into the interventions, and 72 h post-intervention (n 
13). Data are mean  standard error of the mean. *Denotes a significant
treatment effect (p  0.05) versus placebo (baseline values assessed before
treatment were not included in analysis of variance).ations (47). rIntegrins and selectins expressed on both the leukocytes
nd endothelium play an important role in mediating
therosclerosis in response to inflammatory stimuli, through
pecific roles in the cell adhesion cascade. CD11b present
n leukocytes is required for firm adhesion to ICAM-1 on
he inflamed endothelium (48,49). Recent evidence suggests
hat CD11b may also interact with VCAM-1 on the
ndothelium in the presence of elevated glucose levels (50).
revious studies have demonstrated that CD11b expression
n circulating leukocytes is up-regulated in diabetes (51,52)
nd along with the increased production of pro-inflammatory
ytokines (53) suggests an underlying chronic inflammatory
tate that may contribute to vascular disease progression. We
urther demonstrate anti-inflammatory actions of rHDL
nfusion in vivo, with a significant reduction in peripheral
lood monocyte CD11b expression and a reduction in
D11b-dependent leukocyte adhesion to fibrinogen matrix
fter rHDL infusion. This may be relevant in the context of
onocyte rolling and adhesion to the endothelial surface,
here CD11b expression is associated with atherosclerotic
nitiation and progression (54). Similar reductions in mono-
yte CD11b to that observed in the current study occur in
ypercholesterolemia after statin administration (55,56).
iven the concomitant decreases in adhesion molecule
xpression on endothelial cells, and CD11b expression and
ctivity on leukocytes, rHDL infusion may contribute to a
eduction in leukocyte rolling and adhesion.
Despite clear demonstration of the anti-inflammatory
apacity of rHDL infusion on in vitro endothelial cells and
irculating leukocytes, we observed only a minor change in
lasma sVCAM-1 and no significant change in plasma
ICAM-1 or C-reactive protein. These data are not surpris-
ng, however, given the diluting effects of total blood
olume, thus emphasizing that peripheral blood levels of
hese markers are relatively insensitive in reflecting endo-
helial inflammation. This likely also results from the
easurement of soluble forms of these proteins, which only
eflect the amounts cleaved from endothelial cells.
In contrast to the anti-inflammatory data, the capacity of
ost-rHDL infusion plasma to efflux cholesterol to THP-1
acrophages was not closely correlated to apoA-I plasma
oncentration. The pattern of cholesterol efflux in relation
o apoA-I and HDL plasma concentration suggests that
aximal cholesterol efflux capacity was achieved at plasma
oncentrations of HDL and apoA-I achieved as early as 1 h
nto the rHDL infusion. Intracellular cholesterol is deter-
ined by both cholesterol efflux and cholesterol influx, plus
ompensatory changes in cholesterol biosynthesis; only the
ormer was assessed in this study. It is, however, likely that
n increased capacity of plasma to promote cholesterol efflux
ombined with no changes in parameters of forward cho-
esterol transport (such as plasma LDL cholesterol levels)
ill shift the balance of cholesterol toward slower accumu-
ation or reduction of intracellular cholesterol content. This
as recently confirmed in a separate study where infusion ofHDL caused a significant reduction in the cholesterol
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Reconstituted HDL Is Anti-Inflammatory March 17, 2009:962–71ontent of superficial femoral artery plaques in patients with
eripheral vascular disease (57).
tudy limitations. One limitation in our study is that the
ltracentrifugation process results in the isolation of larger
lpha-migrating HDL particles, but smaller pre-beta mi-
rating HDL particles are lost. Previous studies have dem-
nstrated that infusions of rHDL in humans do indeed
esult in the early generation of pre-beta migrating particles
20), which may display anti-inflammatory effects. The
apacity for pre-beta migrating HDL particles to inhibit
nflammation is not known, possibly because of the com-
lexity of isolating such short-lived particles. However, we
annot eliminate the possibility that these particles may be
odulating some of the observed effects.
The conclusions from this study are restricted to the acute
ffects of rHDL infusion in patients with type 2 diabetes.
hether the observed anti-inflammatory and cholesterol
fflux effects are sustained with chronic treatment in other
opulations and translate to significant athero-protection in
ivo remains to be determined.
onclusions
n summary, this study highlights the important and sig-
ificant anti-inflammatory effects of rHDL infusions on
lasma HDL in diabetic individuals, which are related to an
ncrease in its plasma concentration and persist even up to
2 h post-infusion. In addition, rHDL also reduced mono-
yte activation, neutrophil adhesion, and enhanced ex vivo
holesterol efflux. Thus infusions of rHDL may not only
ave therapeutic utility in reducing atheroma burden, but
ay also be used to suppress the widespread vascular
nflammation that characterizes the acute coronary and
erebrovascular syndromes.
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